Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, Galectine-3 and NLRP3-MyD88-chemokine pathways.
Vincenzo Quagliariello(Cancer Institute (WIA)), Nicola Maurea(Cancer Institute (WIA)), Ciro Cipullo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Andrea Paccone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Annabella Di Mauro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alessandro Inno(Ospedale Sacro Cuore Don Calabria), Claudia De Lorenzo(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Margherita Passariello(Federico II University Hospital)
Cited by 2
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
|Critical Reviews in Oncology/Hematology|2019|164
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108
Resveratrol in Cancer Patients: From Bench to Bedside
|International Journal of Molecular Sciences|2020|105